Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

Completed

Conditions studied: Breast Cancer

In brief

The goal of this laboratory research study is to identify possible differences in a gene among patients with breast cancer that cannot be treated by surgery. Researchers want to find out if differences in this gene may increase the risk of side effects from capecitabine.

Key facts

Study ID

NCT00478686

Run by

M.D. Anderson Cancer Center

People needed

102

Starts

2007-05-23

Expected to finish

2017-05-02

Last updated by the study team

2017-05-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be registered for protocol ID 01-580 and only patients who were randomized to receive capecitabine will be included in the study.
• Patients must sign an informed consent for this protocol.

You may not qualify if…

• There are no exclusion criteria.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.